PMID- 28900509
OWN - NLM
STAT- MEDLINE
DCOM- 20180710
LR  - 20181113
IS  - 1838-7640 (Electronic)
IS  - 1838-7640 (Linking)
VI  - 7
IP  - 13
DP  - 2017
TI  - Biodegradable Hollow Mesoporous Silica Nanoparticles for Regulating Tumor 
      Microenvironment and Enhancing Antitumor Efficiency.
PG  - 3276-3292
LID - 10.7150/thno.19987 [doi]
AB  - There is accumulating evidence that regulating tumor microenvironment plays a 
      vital role in improving antitumor efficiency. Herein, to remodel tumor immune 
      microenvironment and elicit synergistic antitumor effects, lipid-coated 
      biodegradable hollow mesoporous silica nanoparticle (dHMLB) was constructed with 
      co-encapsulation of all-trans retinoic acid (ATRA), doxorubicin (DOX) and 
      interleukin-2 (IL-2) for chemo-immunotherapy. The nanoparticle-mediated 
      combinational therapy provided a benign regulation on tumor microenvironment 
      through activation of tumor infiltrating T lymphocytes and natural killer cells, 
      promotion of cytokines secretion of IFN-gamma and IL-12, and down-regulation of 
      immunosuppressive myeloid-derived suppressor cells, cytokine IL-10 and TGF-beta. 
      ATRA/DOX/IL-2 co-loaded dHMLB demonstrated significant tumor growth and 
      metastasis inhibition, and also exhibited favorable biodegradability and safety. 
      This nanoplatform has great potential in developing a feasible strategy to 
      remodel tumor immune microenvironment and achieve enhanced antitumor effect.
FAU - Kong, Miao
AU  - Kong M
AD  - Tongji School of Pharmacy, Huazhong University of Science and Technology, Wuhan 
      430030, China.
AD  - Department of Pharmacy, Sanmenxia Central Hospital, Sanmenxia 472000, China.
FAU - Tang, Jiamin
AU  - Tang J
AD  - China Three Gorges University, Yichang 443002, China.
FAU - Qiao, Qi
AU  - Qiao Q
AD  - Tongji School of Pharmacy, Huazhong University of Science and Technology, Wuhan 
      430030, China.
FAU - Wu, Tingting
AU  - Wu T
AD  - Tongji School of Pharmacy, Huazhong University of Science and Technology, Wuhan 
      430030, China.
FAU - Qi, Yan
AU  - Qi Y
AD  - Tongji School of Pharmacy, Huazhong University of Science and Technology, Wuhan 
      430030, China.
FAU - Tan, Songwei
AU  - Tan S
AD  - Tongji School of Pharmacy, Huazhong University of Science and Technology, Wuhan 
      430030, China.
AD  - National Engineering Research Center for Nanomedicine.
FAU - Gao, Xueqin
AU  - Gao X
AD  - Tongji School of Pharmacy, Huazhong University of Science and Technology, Wuhan 
      430030, China.
FAU - Zhang, Zhiping
AU  - Zhang Z
AD  - Tongji School of Pharmacy, Huazhong University of Science and Technology, Wuhan 
      430030, China.
AD  - National Engineering Research Center for Nanomedicine.
AD  - Hubei Engineering Research Center for Novel Drug Delivery System, Huazhong 
      University of Science and Technology, Wuhan 430030, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20170723
PL  - Australia
TA  - Theranostics
JT  - Theranostics
JID - 101552395
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Biocompatible Materials)
RN  - 0 (Cytokines)
RN  - 0 (Interleukin-2)
RN  - 0 (Lipid Bilayers)
RN  - 7631-86-9 (Silicon Dioxide)
RN  - 80168379AG (Doxorubicin)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/pharmacokinetics/*pharmacology/therapeutic use
MH  - Biocompatible Materials/*chemistry
MH  - Cell Line, Tumor
MH  - Cytokines/metabolism
MH  - Dendritic Cells/drug effects/metabolism
MH  - Disease Models, Animal
MH  - Doxorubicin/pharmacokinetics/pharmacology/therapeutic use
MH  - Drug Liberation
MH  - Humans
MH  - Immunity/drug effects
MH  - Interleukin-2/metabolism
MH  - Lipid Bilayers/chemistry
MH  - Melanoma, Experimental/drug therapy/immunology/pathology
MH  - Mice, Inbred C57BL
MH  - Myeloid-Derived Suppressor Cells/metabolism
MH  - Nanoparticles/*chemistry/ultrastructure
MH  - Neoplasm Metastasis
MH  - Porosity
MH  - Silicon Dioxide/*chemistry
MH  - Tissue Distribution/drug effects
MH  - Tumor Microenvironment/*drug effects
PMC - PMC5595131
OTO - NOTNLM
OT  - cancer treatment.
OT  - drug delivery
OT  - immunosuppression
OT  - nanoparticles
OT  - tumor microenvironment
COIS- Competing Interests: The authors have declared that no competing interest exists.
EDAT- 2017/09/14 06:00
MHDA- 2018/07/11 06:00
PMCR- 2017/01/01
CRDT- 2017/09/14 06:00
PHST- 2017/03/08 00:00 [received]
PHST- 2017/05/29 00:00 [accepted]
PHST- 2017/09/14 06:00 [entrez]
PHST- 2017/09/14 06:00 [pubmed]
PHST- 2018/07/11 06:00 [medline]
PHST- 2017/01/01 00:00 [pmc-release]
AID - thnov07p3276 [pii]
AID - 10.7150/thno.19987 [doi]
PST - epublish
SO  - Theranostics. 2017 Jul 23;7(13):3276-3292. doi: 10.7150/thno.19987. eCollection 
      2017.